This site is intended only for healthcare professionals resident in the Republic of Ireland
Menu
Close
Menu
Close
Safety Profile Summary
Prescribing Information
Adult Dosing
Consistent dosing across indications1
Zavicefta is administered by intravenous infusion over 120 minutes in an appropriate infusion volume (see section 6.6 of SmPC).
Recommended dose for adult patients with estimated CrCl >50 mL/min*
* CrCL estimated using the Cockcroft-Gault formula.
# To be used in combination with metronidazole when anaerobic pathogens are known or suspected to be
contributing to the infectious process.
† To be used in combination with an antibacterial agent active against Gram-positive pathogens when
these are known or suspected to be contributing to the infectious process.
§ The total duration shown may include intravenous Zavicefta followed by appropriate oral therapy.
** There is very limited experience with the use of Zavicefta for more than 14 days.
Recommended dose for adults with estimated CrCL* ≤ 50 mL/min
* CrCL estimated using the Cockcroft-Gault formula.
# Dose recommendations are based on pharmacokinetic modelling (see section 5.2 of SmPC).
† Ceftazidime and avibactam are removed by haemodialysis (see sections 4.9 and 5.2 of SmPC). Dosing of
Zavicefta on haemodialysis days should occur after completion of haemodialysis.
§ Ceftazidime/avibactam is a combination product in a fixed 4:1 ratio and dosage recommendations are
based on the ceftazidime component only (see section 6.6 of SmPC)
No dose adjustment required in the elderly patients and those with hepatic impairment.1
ZAVICEFTA. Summary of Product Characteristics.
Legal Category: S1A
Further information available upon request
Adverse events should be reported.
If you wish to make a medical information inquiry or report an adverse event please contact Pfizer on 1800 633 363
or email Pfizer at [email protected] or visit www.PfizerMedicalInformation.ie
Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.
This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie
This website is brought to you by Pfizer Healthcare Ireland Unlimited Company, The Watermarque Building, Ringsend Road, Dublin 4, Dublin, Ireland, D04 K7N3. Registered in the Republic of Ireland No. 127002. Directors: D. Mangone (Managing), O. Gavan, D. Kennedy. Company Secretary: M.Byrne.
Copyright © 2024 Pfizer Limited. All rights reserved.
The information on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland and contains promotional content.
I confirm that I am a healthcare professional* resident in the Republic of Ireland.
If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland Unlimited Company.
*The IPHA Code definition of a healthcare professional is a person of any of the following classes: (i) Registered medical practitioners (ii) Registered dentists (iii) Registered pharmacists (iv) Registered nurses
Terms of use
PP-UNP-IRL-0891. February 2025